FI972434A0 - Farmaceutisk komposition innehållande lamotrigin - Google Patents
Farmaceutisk komposition innehållande lamotriginInfo
- Publication number
- FI972434A0 FI972434A0 FI972434A FI972434A FI972434A0 FI 972434 A0 FI972434 A0 FI 972434A0 FI 972434 A FI972434 A FI 972434A FI 972434 A FI972434 A FI 972434A FI 972434 A0 FI972434 A0 FI 972434A0
- Authority
- FI
- Finland
- Prior art keywords
- pct
- pharmaceutical composition
- composition containing
- lamotrigine
- containing lamotrigine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9424766.5A GB9424766D0 (en) | 1994-12-07 | 1994-12-07 | Pharmaceutical composition |
PCT/GB1995/002865 WO1996017611A1 (en) | 1994-12-07 | 1995-12-07 | Pharmaceutical composition comprising lamotrigine |
Publications (2)
Publication Number | Publication Date |
---|---|
FI972434A0 true FI972434A0 (sv) | 1997-06-06 |
FI972434A FI972434A (sv) | 1997-06-09 |
Family
ID=10765604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI972434A FI972434A (sv) | 1994-12-07 | 1997-06-06 | Farmaceutisk komposition innehållande lamotrigin |
Country Status (19)
Country | Link |
---|---|
US (1) | US5861179A (sv) |
EP (1) | EP0797441B1 (sv) |
JP (1) | JP2977284B2 (sv) |
CN (1) | CN1174505A (sv) |
AT (1) | ATE213633T1 (sv) |
AU (1) | AU696406B2 (sv) |
BR (1) | BR9509975A (sv) |
CA (1) | CA2207284A1 (sv) |
CZ (1) | CZ171797A3 (sv) |
DE (1) | DE69525649T2 (sv) |
ES (1) | ES2172600T3 (sv) |
FI (1) | FI972434A (sv) |
GB (1) | GB9424766D0 (sv) |
HU (1) | HUT77367A (sv) |
NO (1) | NO972623L (sv) |
NZ (1) | NZ296573A (sv) |
PL (1) | PL320560A1 (sv) |
RU (1) | RU2160106C2 (sv) |
WO (1) | WO1996017611A1 (sv) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
DE19603984A1 (de) * | 1996-02-05 | 1997-08-07 | Bayer Ag | Granulate von Triazinen |
WO1998036737A1 (en) * | 1997-02-25 | 1998-08-27 | The Procter & Gamble Company | Wet granulating method |
AU5026599A (en) * | 1998-07-23 | 2000-02-14 | Novo Nordisk A/S | A wet granulation method for preparing a stable pharmaceutical formulation |
DE60029785T2 (de) * | 1999-06-21 | 2007-08-02 | The Procter & Gamble Company, Cincinnati | Verfahren zur herstellung von reinigungsmittelgranulaten in einem wirbelschichtgranulator mit rückführung von unproportionierten teilchen |
EP1390355A4 (en) * | 2001-02-27 | 2005-02-23 | Teva Pharma | NEW CRYSTALLINE FORMS OF LAMOTRIGIN AND METHOD FOR THE PRODUCTION THEREOF |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
ATE357217T1 (de) * | 2002-04-23 | 2007-04-15 | Teva Pharma | Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
EP1608342A2 (en) * | 2003-03-21 | 2005-12-28 | Ranbaxy Laboratories, Ltd. | Stable lamotrigine pharmaceutical compositions and processes for their preparation |
WO2004103340A1 (en) * | 2003-05-20 | 2004-12-02 | Ranbaxy Laboratories Limited | Water dispersible tablets of lamotrigine |
TR201910177T4 (tr) | 2003-09-12 | 2019-08-21 | Amgen Inc | Bir sinakalset HCl içeren hızlı çözünme formülasyonu. |
US20070225727A1 (en) * | 2004-05-31 | 2007-09-27 | Keiichi Matsuhisa | Transparent Tissue-Visualizng Preparation |
WO2008104996A2 (en) * | 2007-02-28 | 2008-09-04 | Jubilant Organosys Limited | Water dispersible pharmaceutical formulation and process for preparing the same |
US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
US20130108697A1 (en) | 2010-03-04 | 2013-05-02 | Ramakant Kashinath Gundo | Modified release dosage form |
EP3525792A4 (en) | 2016-10-11 | 2020-04-22 | Aucta Pharmaceuticals | POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3637688A (en) * | 1970-01-09 | 1972-01-25 | American Home Prod | 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines |
CS234018B2 (en) * | 1979-06-01 | 1985-03-14 | Wellcome Found | Method of 3,5-diammino-6-1,2,4-triazine derivatives making |
FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
DE69016283T3 (de) * | 1989-06-30 | 1998-04-02 | Sumitomo Electric Industries | Substrat mit einer supraleitenden Schicht. |
SK282071B6 (sk) * | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Tableta dispergovateľná vo vode a spôsob jej prípravy |
CA2277722C (en) * | 1991-11-22 | 2001-03-27 | The Wellcome Foundation Limited | Water dispersible tablets |
GB9203483D0 (en) * | 1992-02-19 | 1992-04-08 | Wellcome Found | Anti-inflammatory compounds |
FR2699077B1 (fr) * | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
FR2700114A1 (fr) * | 1993-01-07 | 1994-07-08 | Rhone Poulenc Rorer Sa | Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
GB9305693D0 (en) * | 1993-03-19 | 1993-05-05 | Wellcome Found | Therapeutic triazine compounds and use |
GB9305692D0 (en) * | 1993-03-19 | 1993-05-05 | Wellcome Found | Therapeutic triazine compounds and use |
FR2702149B1 (fr) * | 1993-06-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application de la lamotrigine dans le traitement du neuro-sida. |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
-
1994
- 1994-12-07 GB GBGB9424766.5A patent/GB9424766D0/en active Pending
-
1995
- 1995-12-07 US US08/849,070 patent/US5861179A/en not_active Expired - Fee Related
- 1995-12-07 CZ CZ971717A patent/CZ171797A3/cs unknown
- 1995-12-07 ES ES95939352T patent/ES2172600T3/es not_active Expired - Lifetime
- 1995-12-07 AT AT95939352T patent/ATE213633T1/de not_active IP Right Cessation
- 1995-12-07 JP JP8517420A patent/JP2977284B2/ja not_active Expired - Lifetime
- 1995-12-07 HU HU9702196A patent/HUT77367A/hu unknown
- 1995-12-07 NZ NZ296573A patent/NZ296573A/xx unknown
- 1995-12-07 WO PCT/GB1995/002865 patent/WO1996017611A1/en not_active Application Discontinuation
- 1995-12-07 BR BR9509975A patent/BR9509975A/pt not_active Application Discontinuation
- 1995-12-07 RU RU97111870/14A patent/RU2160106C2/ru active
- 1995-12-07 EP EP95939352A patent/EP0797441B1/en not_active Expired - Lifetime
- 1995-12-07 DE DE69525649T patent/DE69525649T2/de not_active Expired - Fee Related
- 1995-12-07 CN CN95197473A patent/CN1174505A/zh active Pending
- 1995-12-07 CA CA002207284A patent/CA2207284A1/en not_active Abandoned
- 1995-12-07 PL PL95320560A patent/PL320560A1/xx unknown
- 1995-12-07 AU AU41211/96A patent/AU696406B2/en not_active Ceased
-
1997
- 1997-06-06 NO NO972623A patent/NO972623L/no not_active Application Discontinuation
- 1997-06-06 FI FI972434A patent/FI972434A/sv unknown
Also Published As
Publication number | Publication date |
---|---|
DE69525649T2 (de) | 2002-09-05 |
JP2977284B2 (ja) | 1999-11-15 |
AU4121196A (en) | 1996-06-26 |
PL320560A1 (en) | 1997-10-13 |
CA2207284A1 (en) | 1996-06-13 |
HUT77367A (hu) | 1998-03-30 |
CN1174505A (zh) | 1998-02-25 |
RU2160106C2 (ru) | 2000-12-10 |
GB9424766D0 (en) | 1995-02-08 |
MX9704103A (es) | 1997-09-30 |
EP0797441A1 (en) | 1997-10-01 |
NO972623D0 (no) | 1997-06-06 |
CZ171797A3 (en) | 1997-11-12 |
JPH10510255A (ja) | 1998-10-06 |
ES2172600T3 (es) | 2002-10-01 |
US5861179A (en) | 1999-01-19 |
NO972623L (no) | 1997-08-06 |
FI972434A (sv) | 1997-06-09 |
BR9509975A (pt) | 1998-06-09 |
NZ296573A (en) | 1997-08-22 |
EP0797441B1 (en) | 2002-02-27 |
AU696406B2 (en) | 1998-09-10 |
DE69525649D1 (de) | 2002-04-04 |
ATE213633T1 (de) | 2002-03-15 |
WO1996017611A1 (en) | 1996-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
FI972434A0 (sv) | Farmaceutisk komposition innehållande lamotrigin | |
FI960102A0 (sv) | En ny farmaceutisk blandning | |
HU9603228D0 (en) | Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies | |
ZA948670B (en) | New benzoyl guanidine derivatives,the preparation thereof and their use in pharmaceutical compositions | |
FI964332A (sv) | Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes | |
ZA965997B (en) | N-(4-substituted-benzyl)-2-aminolactam derivatives | |
UA41978C2 (uk) | N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція | |
DK0561846T3 (da) | 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning | |
IL112999A0 (en) | Crystalline salts of 2,3,4,5- tetrahydro -1h-3-benzazepine compounds, their preparation and pharmaceutical compositions containing them | |
DK0866711T3 (da) | Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö | |
IL108288A0 (en) | Pyrrolidine derivatives, their preparation and medicaments containing them | |
BR9306870A (pt) | Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol | |
IL108283A0 (en) | Use of riluzole for promoting restoration following radiation | |
JO1653B1 (en) | The current benzimidazole is a therapeutically active method for preparing it |